Donor lymphocyte infusion (DLI) after allogeneic SCT induces complete remissions in approximately 80% of patients with relapsed CML in chronic phase, but some patients do not respond to DLI. We studied absolute numbers of dendritic cell (DC) subsets and chimerism in T cells and two subsets of blood DCs (myeloid DCs (MDCs) and plasmacytoid DCs (PDCs)) in relation to DLI-induced alloreactivity. Based on T cell and DC chimerism, we identified three groups. Four patients were completely donor chimeric in T cells and DC subsets. These patients had an early stage of relapse, and three of the four patients attained complete molecular remission (CMolR) without significant GVHD. Six patients were completely donor in T cells and mixed chimeric in DC subsets. All patients entered CMolR, but this was associated with GVHD in four and cytopenia in three patients. Five patients had mixed chimerism in T cells and complete recipient chimerism in MDC; only two patients entered CMolR. Our data suggest that the combination of donor T cells and mixed chimerism in DC subsets induces a potent graft-versus-leukemia (GVL) effect in association with GVHD. DLI in patients with an early relapse and donor chimerism in both T cells and DC subsets results in GVL reactivity without GVHD.
Introduction
Donor lymphocyte infusion (DLI) is used to boost graftversus-leukemia (GVL) reactivity in patients with a relapse after allogeneic SCT. Following DLI, complete molecular remission (CMolR) has been obtained in 70-80% of patients with a relapse of CML in chronic phase. 1 In contrast, patients with a CML in accelerated phase or blast crisis, patients with relapsed acute leukemia and patients with relapsed or persistent multiple myeloma respond in only 10-40% of cases. 2 The mechanisms responsible for the different DLI-mediated anti-tumor responses between various disease types are still unclear. Differences in tumor characteristics such as growth rate, susceptibility to T cellmediated cytotoxicity, secretion of immune-modulatory cytokines and expression of co-stimulatory molecules may have a major impact on the response. [3] [4] [5] Another important factor that may contribute to the response rate is the chimerism in immune effector and professional antigenpresenting cells (APC) at the time of DLI. Murine studies showed that recipient APC play a key role in the initiation of allogeneic CD8 þ T cell-mediated GVH and GVL reactivity after MHC-matched SCT. 6, 7 In addition, in an MHC-mismatched mouse model, it has been shown that DLI administration to mixed chimeras produced improved leukemia-free survival compared to administration of DLI to full donor chimeras. 8 From these data, it can be hypothesized that the presence of recipient APC may be an important factor for the induction of DLI-induced GVL reactivity.
Dendritic cells (DC) are the most potent bone marrowderived APC that play a pivotal role in inducing primary immune responses. In human blood, DC precursors constitute less than 1% of lineage-negative human leukocyte antigen (HLA)-DR þ mononuclear cells, and are commonly divided into two distinct subsets, namely myeloid DC (MDC) and plasmacytoid DC (PDC). MDCs have a monocytoid appearance and express myeloid antigens such as CD11c, CD13 and CD33. In contrast, PDC lack myeloid markers, but express CD123 (interleukin-3 receptor-a), and have a plasma cell-like morphology. 9, 10 MDC and PDC can be distinguished in peripheral blood using the monoclonal antibodies BDCA-1 (CD1c) for MDC, and BDCA-2 and BDCA-4 for PDC. 11 Emerging evidence suggests that MDC and PDC play an important role in alloimmune responses after SCT. 12 In this study, we evaluated the absolute number and chimerism of peripheral blood T cells, MDC and PDC in patients with a relapse from CML before the administration of donor lymphocytes. Our hypothesis, based on animal models, is that the presence of recipient MDC and/ or PDC is associated with the induction of a more efficient GVL reaction.
Patients and methods

Patients and donors
Chimerism of hematopoietic cell populations was studied in 15 CML patients with a relapse after partially T celldepleted allogeneic SCT. In five patients (two with molecular relapse and three with cytogenetic relapse), remission after SCT was confirmed with a negative quantitative PCR for BCR-ABL. In five patients, PCR was performed, but not on a quantitative level. In five other patients, no PCR was performed between SCT and relapse.
These relapsed CML patients received DLI, and were selected on the availability of cryopreserved peripheral blood mononuclear cell (PBMC) samples obtained shortly before DLI. DLIs were given in a period from January 1996 until November 2003. All patients were treated initially with allogeneic SCT for CML in first chronic phase. The median duration between diagnosis and SCT was 9 months (range ¼ 3-17). The median age of patients was 40 years (range ¼ 26-51) at the time of SCT. Stem cell donors were HLA identical siblings in 11 of the 15 patients. One patient received G-CSF mobilized PBSCs, and the other 14 patients received bone marrow stem cells. One patient received bone marrow stem cells from a one HLA class I locus-mismatched sibling. Two patients were transplanted with stem cells from HLA identical unrelated donors and one patient received stem cells from a phenotypically identical father. The median age of the donors was 36 years (range ¼ 19-70) at the time of stem cell donation. Clinical characteristics of patients and donors are shown in Table 1 .
Conditioning regimen and GVHD prophylaxis
The standard conditioning consisted of cyclophosphamide 60 mg/kg body weight intravenously on each of the two consecutive days followed by fractionated total body irradiation (TBI) in two equal fractions of 4.5 Gy on 2 days. In nine patients, the conditioning regimen was intensified with the addition of idarubicin to a total dose of 42 mg/m 2 body surface given by continuous intravenous infusion. Two patients transplanted with stem cells from an unrelated donor received anti-thymocyte globulin (thymoglobulin, Genzyme Europe, Naarden, The Netherlands) 2 mg/kg intravenously on each of four consecutive days in addition to the standard regimen. In the patients receiving stem cells from a one locus-mismatched or a haplo-identical donor, the conditioning regimen consisted of cyclophosphamide, TBI plus total lymphoid irradiation 2 Â 2 Gy on each of the two consecutive days. All patients received cyclosporine A for GVHD prophylaxis. The grafts were partially depleted of T cells by counterflow centrifugation as described before. 13 Further details on conditioning, T cell content and on the quality of the grafts are given in Table 1 .
Infusion of donor lymphocytes DLI was performed as described before.
14 Briefly, donor lymphocytes were obtained from the original stem cell donor by leukapheresis using the blood cell separator Baxter CS 3000 (Baxter, Deerfield, IL, USA) or the Fresenius AS 104 (Fresenius, Oberursel, Germany). Lymphocytes were administered to the patient within 3 h of completion of the leukapheresis procedure. No GVHD prophylaxis was administered after the infusion of the donor lymphocytes. If a patient did not respond to the first DLI, a second or third DLI was given in escalating doses of T lymphocytes. The first dose ranged from 0.1 to 0.7 Â 10 8 CD3 þ cells/kg for patients with a hematological or cytogenetic relapse. The second dose ranged from 0.7 to 1.0 Â 10 8 CD3 þ cells/kg. For patients with an unrelated donor, the first dose ranged from 0.05 to 0.1 Â 10 8 CD3 þ cells/kg. Median time between relapse and the first DLI was 1.4 months (range ¼ 0,2-39.1). There was a long interval of 39.1 months in the patient transplanted with stem cells from a phenotypically identical farther, because this patient had a history of acute and chronic GVHD and aspergillus infection at the time of relapse.
Cytogenetic analysis and quantification of BCR-ABL-positive cells Chromosome studies on peripheral blood and bone marrow cells were performed after SCT and DLI as described before. 15 In sex-mismatched donor-patient pairs, heterosome determination of 400 interphases with fluorescence in situ hybridization (FISH) allowed additional differentiation between donor and recipient cells. If more than five autologous marrow interphases were found, bone marrow cells were analyzed for the presence of the Philadelphia chromosome using BCR-ABL probes. For quantification of BCR-ABL-positive cells, total RNA from peripheral blood cells was extracted using Trizol (Invitrogen, Carlsbad, CA, USA). Real-time PCR analysis was performed on an ABI/Prism 7700 system (Applied Biosystems, Foster City, CA, USA), as described previously. 16 Expression of the porphobilinogen deaminase (Pbgd) gene was used to normalize BCR-ABL expression. This normalized BCR-ABL expression in patient samples was related to a standard curve obtained from K562 cells diluted into normal bone marrow cells. The limit of detection of BCR-ABL PCR is 1 Â 10
À5
.
Quantification of DC subsets
Blood samples were obtained from patients shortly before DLI. PBMC were isolated by Ficoll-Paque (Pharmacia, Uppsala, Sweden), cryopreserved and stored in liquid nitrogen until use. DC subsets were enumerated using thawed PBMC by three-color immunofluorescence analysis. The following mAbs were used: FITC-conjugated anti-CD45 (J33), anti-CD14 (TÜ K4) (Beckman Coulter, Mijdrecht, The Netherlands), PE-conjugated anti-CD1c (BDCA-1, AD5-8E7), BDCA-2, BDCA-4 (AC144 and AD5-17F6; Miltenyi Biotech, Bergisch Gladbach, Germany), Cy5-conjugated anti-CD19 (J4.119) and anti-CD45 (J33) (Beckman Coulter). PBMC were incubated with the appropriate concentration of mAb in phosphatebuffered saline (PBS) supplemented with 20% pooled human serum and 0.1% NaN 3 (41C for 30 min). Cells were washed in PBS/1% bovine saline albumin and analyzed using a Coulter XL flow cytometer (Beckman Coulter, Fullerton, CA, USA). MDCs and PDCs were identified as CD45 þ BDCA-1 þ CD19À and CD457 þ BDCA-2/4 þ CD14À mononuclear cells, respectively. Absolute number was calculated by multiplying the percentage of MDC and PDC with the total number of mononuclear cells per liter.
Purification of PBMC subsets PBMC subsets were isolated using a two-step flow cytometric cell-sorting procedure that allows purification of five different subsets. PBMC were labeled with a mixture of Cy5-conjugated mAb against the lineage markers CD2 (39C1.5), CD20 (B9E9), CD15 (80H5) (Beckman Coulter), and FITC-conjugated anti-CD11c (KB90; DAKO, Glostrup, Denmark) mAb. Labeled cells were sorted into three fractions, that is CD11c þ LinÀ, CD11c-LinÀ and Lin þ cells, using the Coulter Epics Altra hypersort flow cytometer (Beckman Coulter). These pre-sorted cell fractions were subsequently stained with the appropriate concentration of PE, Cy5 and ECD-conjugated mAb, and different subsets were sorted using the Coulter Epics Elite flow cytometer (Beckman Coulter). The Lin þ cell fraction was used to isolate CD3 þ T cells (CD3-ECD, UCHT1; Beckman Coulter) and CD13.CD33 þ myeloid cells (CD13-PE, SJ1D1, and CD33-PE, D3HL60.251; Beckman Coulter). MDCs were isolated from the CD11c þ Lin-cell fraction based on expression of BDCA-1 (BDCA-1-PE, AD5-8E7; Miltenyi Biotec) and negativity for CD19 (CD19-Cy5, J4.119; Beckman Coulter). PDCs were isolated from the CD11c-Lin-cell fraction based on expression of BDCA-2 (BDCA-2-PE, AC144; Miltenyi Biotec) and BDCA-4 (BDCA-4-PE, AD5-17F6; Miltenyi Biotec) and negativity for CD14 (CD14-Cy5, RMO52; Beckman Coulter). An aliquot of sorted cells was reanalyzed and purity was more than 95% in all cases.
Quantification of the percentage recipient and donor cells in PBMC subsets
Real-time quantitative PCR of single nucleotide polymorphisms (SNP) and/or the SMCY gene was used for the quantification of donor and recipient hematopoietic cells, as described previously. 17, 18 Briefly, recipient/donor pairs were screened for discriminating SNPs. Quantification is based on real-time PCR with allele-specific primers for DNA sequences containing the discriminating SNP and target DNA-specific probes. Quantitative analysis is performed by generating calibration functions from cycle thresholds (C t ) obtained by real-time PCR of DNA serially diluted in water. Detection limit for T cells was 0.1-1% and for DC subpopulations 1-10%, depending on the number of isolated cells.
Definitions
Complete donor chimerism in T cells, myeloid cells and monocytes was defined as o1% recipient cells among donor cells, and complete recipient chimerism as o1% donor cells among recipient cells. For DC subpopulations, complete donor chimerism was defined as o10% recipient cells among donor cells, and complete recipient chimerism as o10% donor cells among recipient cells. Mixed chimerism in T cells, myeloid cells and monocytes was defined as X1% recipient cells and X1% donor cells. For DC subpopulations, mixed chimerism was defined as X10% recipient cells and X10% donor cells. Higher thresholds were chosen for DC subsets because the amount of input DNA obtained from MDC and PDC was lower than from T cells, myeloid cells and monocytes. This lower input of DNA resulted in a lower DC t , and for some samples the limit of detection was o10%.
Acute and chronic GVHD were classified grades I-IV and limited or extensive, respectively, according to the criteria described by Glucksberg et al. 19 and Shulman et al. 20 GVHD after DLI was classified as acute GVHD for the first 3 months after DLI. Cytopenia after DLI was defined as a white blood cell count of o1.0 Â 10 9 /l and/or platelet counts of o15 Â 10 9 /l, and/or a hemoglobin level of o6.0 mmol/l.
Hematological remission of CML was defined as disappearance of all signs and symptoms of disease and normalization of blood cell counts and cellularity of the bone marrow. Complete cytogenetic response (CCyR) was defined as the disappearance of the Philadelphia chromosome in the bone marrow. CMolR was defined as a realtime PCR for the BCR-ABL fusion transcript under the detection level at X2 consecutive points after DLI. Accelerated phase was defined according to the WHO criteria.
Results
Response of CML following DLI Nine of the 15 patients had a hematological relapse at the time of first DLI with a median interval of 15 months (range ¼ 6-64) after SCT ( Table 2) 8 T cells/kg). Six patients were in an accelerated phase, including the non-responding patient and the two patients obtaining CCyR. In four patients, the presence of an accelerated phase is based only on cytogenetic abnormalities, however in three of these four patients, we found del(13) which is typical for CML. One patient had 12% blasts in bone marrow and multiple structural cytogenetic abnormalities, and one patient presented with thrombocytosis unresponsive to therapy (treatment with hydroxyurea).
Four patients had a cytogenetic relapse at the time of first DLI with a median interval of 24 months (range ¼ 10-37) after SCT. Two of these four patients attained CMolR after first DLI ( The mean number of T cells/kg (first and eventually second DLI) did not differ between the group of patients with GVHD and without GVHD; 0. The doses of the first DLI's were low in patients with an unrelated and haplo-identical donor, and these three patients did not develop GVHD. The patient receiving Table 2 Disease status at the time of first and second (in non-responding patients) DLI, interval SCT-DLI, T-cell dose of DLI and response to DLI For the group with GVHD, the median time between SCT and DLI-1 was 17 months (range ¼ 9-37). For the patients without GVHD, the median time between SCT and DLI-1 was 24 months (range ¼ 9-64) (no significant difference, P ¼ 0.41 according to the Mann-Whitney test).
UPN
Pre-DLI T cell chimerism and disease response Previously, we showed that the percentage of T cells from donor origin at the time of DLI correlates with response, and that the presence of significant numbers of recipient T cells is unfavorable. 23 Therefore, we analyzed T cell chimerism in these 15 CML patients.
Five patients had mixed T cell chimerism at the time of first or second DLI (Table 3 ) and only two attained CMolR (40%). The remaining 10 patients had complete T cell donor chimerism at the time of first or second DLI, and all but one obtained a CMolR (90%, P ¼ 0.07; Fisher's exact test). These data suggest that in relapsed CML patients the presence of autologous T cells indicates reduced effectiveness of DLI.
Pre-DLI T cell and DC chimerism
To analyze the role of recipient-derived DC, we divided the patients with donor T cells in a group with donor chimerism in MDC and PDC (group 1) and a group with the presence of recipient DC (group 2) ( Table 3 ). The four patients in group 1 had either a molecular (n ¼ 2) or a cytogenetic relapse (n ¼ 2), indicating an early stage of relapse. Three of the four patients entered CMolR after 1 or 2 DLI's and only one of these four patients developed GVHD grade I. None of these patients developed neither chronic GVHD nor cytopenia.
The six patients in group 2 were complete donor chimeric in T cells and mixed chimeric in MDC and/or PDC. One patient had a cytogenetic relapse and five patients had a hematological relapse. Despite the advanced stage of disease, all patients entered CMolR. However, four of these six patients (66%) developed GVHD and three of the six patients (50%) developed chronic GVHD. The combination of GVL with GVHD may indicate that the DLImediated alloreactivity is stronger in group 2 compared to group 1. Furthermore, three patients developed pancytopenia. The cytopenia may be explained by the eradication of the malignant clone and the slow recovery of the normal donor hematopoiesis. Moreover, cytopenia is indicative for the tumor load and a low number of donor hematopoietic cells. 24 Interestingly, in one of the patients of group 2 (UPN 406), we could sort enough DC to perform FISH analysis using probes for BCR-ABL. This patient had mixed chimerism in both MDC (68% recipient-derived) and PDC (37% recipient-derived). In the MDC subset, 8 of the 43 cells (18%) were BCR-ABL positive, and in the PDC subset, 39 of the 164 cells (23%) were BCR-ABL positive, indicating that part of the recipient-derived MDC and PDC originates from malignant CML progenitor cells. The third group consists of five patients with mixed chimerism in the T cells at the time of the first or second DLI. The clinical presentation at the time of the first DLI was a cytogenetic relapse in one patient and a hematological relapse in four patients. Four patients were complete recipient chimeras in the MDC subpopulation. One patient had donor MDC in combination with mixed chimerism in T cells. Two of these five (40%) patients reached CMolR in combination with GVHD. One patient did not respond to DLI and two patients were temporary responders with a second relapse 1.5 and 4 years after the first DLI.
DC numbers at the time of DLI
To investigate the correlation between the absolute numbers of MDC and PDC and DLI-induced alloreactivity, we performed immunophenotyping analysis of PBMC samples obtained shortly before DLI. The median number of MDC and PDC at the time of first DLI was 5.8 Â The patient who did not respond to DLI (UPN 396) and two patients with a second relapse after the initial CCyR (UPN 336 and 389) ultimately progressed to an accelerated or blast phase. At the time of CML progression to an accelerated phase, MDC and PDC numbers were very low (o0.01%).
Discussion
Complete remission after DLI is strongly associated with the occurrence of GVHD, indicating that alloreactive T cells largely mediate GVT reactivity. Studies in MHC-identical murine transplantation models showed that recipient APC are absolutely required to initiate alloreactive CD8 þ Tcell responses mediating GVHD. 6 But once initiated, GVHD can be intensified by donor-derived APC that are capable to cross-present recipient antigens to the primed alloreactive CD8 þ T cells. 7 The same mouse model shows that donor APC do not contribute to the induction of CD8 þ T cellmediated GVT reactivity against chronic-phase CML. 6, 7 These studies clearly show the importance of recipient APC in the induction of allo-immune responses after transplantation. However, little is known about the initiation of alloreactive CD8 þ T cell responses following DLI in the human setting. In a MHC-mismatched mouse model, it has been demonstrated that DLI in mixed hematopoietic chimeras produced improved leukemia-free survival compared to DLI in full-donor chimeras. 8 This suggests that recipient APC present in mixed chimeras at time of DLI may exert more optimal presentation of recipient antigens leading to superior alloactivation of infused donor T cells, whereas absence of recipient APC in full-donor chimeras may result in non-responsiveness. This leads to our hypothesis that the presence of peripheral blood MDC and PDC from recipient origin at the time of DLI is associated with the induction of an efficient GVL reaction.
Based on chimerism analysis, we identified three groups. subsets. They had an early stage of the relapse and three of the four patients obtained CMolR after DLI without significant GVHD. Group 2 was complete donor chimeric in T cells and mixed chimeric in MDC and/or PDC. The six patients in the second group had a more advanced stage of relapse: five had a hematological relapse and one patient had a cytological relapse. All six patients entered CMolR. In this group, the GVL reactivity was associated with clinically overt GVHD in four patients. From these results, we speculate that the combination of donor T cells with donor DC induces mild alloreactivity, which is sufficient for the eradication of early stage of relapse. In contrast, the combination of full-donor T cell chimerism with host MDC and/or PDC induces stronger alloreactivity leading to potent GVL response associated with GVHD. The combination of mixed T cell chimerism with recipientderived MDC is less favorable as shown in the third group. This suggests that in patients with an early relapse, GVL can be separated from GVHD by DLI with low T cell dose in the presence of donor chimerism in T cells and DC subsets. Therefore, these data only partly support our initial hypothesis that recipient-derived DCs are necessary for induction of a DLI-mediated immune response. However, the presence of recipient-derived DC subsets in patients with a cytogenetic or hematological CML relapse may be favorable to induce more potent GVL reactivity for the eradication of higher tumor loads. Further evolution of chimerism to mixed chimerism in T cells is unfavorable and only two of the five patients reach CMolR. Moreover, evolution of chimerism to mixed T cell chimerism is associated with declining absolute MDC numbers indicating that both are related with tumor load of the CML. Our data suggest that the balance between T cells and DC subsets may be important in the initiation of an alloimmune response after DLI. However, chimerism of APC present in lymphoid tissue or GVHD target organs such as skin or gastrointestinal tract may also play a role in the initial priming and intensification of the alloimmune response. 25 Furthermore, recipient-derived monocytes and/ or myeloid (progenitor) cells may exert antigen-presenting function. 21 In all but one patient, the myeloid cell fraction was mixed chimeric or recipient derived, indicating that myelopoiesis had turned to host origin. Another factor is the sensitivity of the real-time PCR for chimerism determination and we might fail to identify minor populations of recipient-derived DC, which could be enough to induce an immune response. Finally, the presence of proinflammatory cytokines and the availability of TLR ligands may influence the activation status of the DC subsets. 26 Six patients developed cytopenia after DLI. Five of these six patients received DLI in the accelerated phase of their disease. Keil et al. 24 showed that a level of about 5% donor cells was enough to protect against critical aplasia after DLI. We did not study chimerism in CD34 þ cells, however, four patients with aplasia had 494% recipientderived myeloid cells in peripheral blood at the time of DLI (data not shown). Two patients had approximately 60% recipient-derived myeloid cells; in one patient, the duration of aplasia was 3 days during an episode with fever; one patient was pre-treated with hydroxyurea.
We showed that part of the recipient-derived MDC and PDC originate from the malignant CML progenitor cells. This situation is specific for CML and is not applicable for relapse of lymphoid malignancies or acute myeloid leukemias. Relapse of lymphoid malignancies or acute leukemias after allogeneic SCT probably show other dynamics of return of recipient cells. As the malignant clone in other malignancies does not produce MDC or PDC, return of recipient-derived DC subsets is less likely.
We performed this study to elucidate the mechanisms that determine the effectiveness of DLI in patients with relapsed CML in relation with DC chimerism. Absolute numbers of MDC and PDC did not correlate with induction of alloreactivity, but median number of MDC was higher in the group of patients with an early relapse. The combination of donor chimerism in T cells and the presence of recipient DC subsets induces efficient GVL reactivity (all patients enter CMolR) in association with GVHD in 66% of the patients. However, in patients with a molecular relapse, low-dose DLI can induce mild alloreactivity, which is enough to reach CMolR without significant GVHD. This study confirms the importance of regular BCR-ABL measurements, for early identification of a molecular relapse. Further studies are needed for a better understanding of factors that influence the effectiveness of DLI and for the development of strategies to enhance the effectivity of DLI in patients with other malignancies than CML.
